TR | Premium Research-Grade Beauty Peptide |Chonluten| 99% Purity | Lyophilized Powder | High Quality | Retatrutide, Tirzepatide,tr 2026000-20-2
1 Inquiries
75007-24-8
99.56%
HongKong
10via/kit
2028-05-18
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceGlu-Asp-Gly is an oligopeptide.Basic Info
-
Product Name:
(4S)-4-amino-5-[[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
Other Name:Glu-Asp-Gly;glutamyl-aspartyl-glycine;H-Glu-Asp-Gly-OH;T-34 tripeptide;Glu-asp-gly;Glutamyl-aspartyl-glycine;75007-24-8;(4S)-4-amino-5-[[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;H-Glu-asp-gly-OH;T-34 tripeptide;L-Glutamyl-L-aspartyl-glycine;SCHEMBL3909775;DTXSID80996513;CHEBI:162780;Glycine, N-(N-L-alpha-glutamyl-L-alpha-aspartyl)-;4-Amino-5-({3-carboxy-1-[(carboxymethyl)imino]-1-hydroxypropan-2-yl}imino)-5-hydroxypentanoic acid
CAS No.:75007-24-8
Molecular Formula:C11H17N3O8
InChIKeys:DSPQRJXOIXHOHK-WDSKDSINSA-N
Molecular Weight:319.27 g/mol
Exact Mass:319.10156451 g/mol
Categories:
Characteristics-
PSA:
196 Ų
XLogP3:-1.1791
Melting Point:143 - 145 °C
Research-
Class:
Dual agonist — GIPR, GLP-1R
Status:FDA-approved (Mounjaro / Zepbound)
Mechanism:Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.
EC50 (Human GLP1R):0.934 nM
EC50 (Human GIPR):0.0224 nM
Source:Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI
Clinical Development:NCT03954834; NCT03987919; NCT03882970; NCT03730662; NCT04039503
FDA:Mounjaro, Zepbound (approved 2022-05-13)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Location:
1502A1, Building 4, Xinyuanxin Center, No. 3 Huaxin Road, Dongfeng Street, Licheng District, Jinan City, Shandong Province
-
Payment Terms:
TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
Certifications:
COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted
United Kingdom
Chonluten
10 PCS Apr 15, 2026 Post an enquiry for this product
Pls input...